LakeShore Biopharma (LSB) said Friday that it has been granted approval by China's National Medical Products Administration for a phase 3 clinical study of a simplified four-dose regimen for its YSJA rabies vaccine.
The biopharmaceutical company said the study will begin in December and will evaluate the immunogenicity and safety of its YSJA rabies vaccine across two four-dose immunization schedules compared with the existing five-dose Essen regimen.
Shares of LakeShore Biopharma were down more than 4% in early trading Friday.
Price: 3.0000, Change: -0.14, Percent Change: -4.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。